SYNEOS HEALTH UK LIMITED

CytoDyn Inc. received FDA clearance for a phase II oncology trial evaluating leronlimab in r/r microsatellite stable colorectal cancer. The trial, in partnership with Syneos Health, will begin patient enrollment in early 2025.

Sales intelligence is crucial for navigating regulatory complexities in clinical trials, aiding in decision-making, and fostering relationships. Investing in robust platforms can redefine a company's trajectory, offering real-time insights and competitive advantages. The market for such solutions is growing, driven by globalisation and technological advancements like AI and blockchain. Leading providers include Veeva Systems, IQVIA, and Medidata Solutions, each offering unique functionalities tailored to specific organisational needs.

Global pediatric clinical trials market size is projected to grow from USD 17.37 billion in 2024 to USD 27.65 billion by 2033, driven by R&D investments, rising pediatric diseases, and strict regulations. Phase II trials dominate, with North America leading and Asia Pacific expected to grow fastest. Key players include Pfizer Inc., QPS Holdings, and LabCorp Drug Development.

CytoDyn received FDA clearance for its Phase II oncology trial evaluating leronlimab in relapsed/refractory microsatellite stable colorectal cancer. The trial, in partnership with Syneos Health, will kick off in late November 2024, with patient enrollment starting in early 2025.

CytoDyn Inc. received FDA clearance for its Phase II oncology trial evaluating leronlimab in relapsed/refractory microsatellite stable colorectal cancer, to be conducted in partnership with Syneos Health, with a trial kickoff in late November 2024 and patient enrollment in early 2025.

EMERGENT trials enrolled adults with schizophrenia, excluding those with treatment resistance or recent non-schizophrenia diagnoses. The 5-week, double-blind, placebo-controlled trials evaluated xanomeline/trospium in the U.S. and Ukraine. Primary endpoint was change in PANSS total score at week 5, with secondary outcomes including PANSS subscale scores and CGI-S score. Statistical analysis used MMRM models, and responder analyses were based on PANSS and CGI-S criteria.

Ophthalmic clinical trials market is growing due to aging populations and screen time, with innovations like AI and telemedicine reshaping trials. Key players include Charles River Laboratories, ICON Plc, and IQVIA. The market offers opportunities for new entrants and collaborations among pharmaceutical companies, universities, and regulatory bodies.

AusBiotech 2024 will feature over 260 speakers and 60 sessions, addressing global biotech trends, research, and industry advancements. Key topics include artificial heart technology, quantum computing in biotech, and medical manufacturing. The event also highlights emerging biotechnologies in agriculture and cell and gene therapies, supported by government initiatives and strategic partnerships. Australia's biotech sector is rapidly advancing, driven by innovation, government support, and strategic geographical clustering near research institutions.